drugset / Trial / NCT04500860

Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up.

NCT04500860

Phase 1 Completed 90 enrolled Kasr El Aini Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

Evaluation of use of low dose tadalafil 5 mg daily for treatment of female OAB syndrome

Timeline

Start
2020-12-01
Primary completion
2022-07-01
Completion
2022-07-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tadalafil Small molecule 5 mg
Comparator Tolterodine Small molecule 4 mg Oral

Indications